- Home
- SNGX vs IBG Comparison
SNGX vs IBG Comparison
Compare SNGX & IBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- IBG
- Stock Information
- Founded
- SNGX 1987
- IBG 2018
- Country
- SNGX United States
- IBG Australia
- Employees
- SNGX N/A
- IBG N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- IBG Beverages (Production/Distribution)
- Sector
- SNGX Health Care
- IBG Consumer Staples
- Exchange
- SNGX Nasdaq
- IBG Nasdaq
- Market Cap
- SNGX 6.5M
- IBG 6.0M
- IPO Year
- SNGX 1987
- IBG 2024
- Fundamental
- Price
- SNGX $1.28
- IBG $0.59
- Analyst Decision
- SNGX
- IBG Strong Buy
- Analyst Count
- SNGX 0
- IBG 1
- Target Price
- SNGX N/A
- IBG N/A
- AVG Volume (30 Days)
- SNGX 2.7M
- IBG 75.6K
- Earning Date
- SNGX 08-08-2025
- IBG 07-22-2025
- Dividend Yield
- SNGX N/A
- IBG N/A
- EPS Growth
- SNGX N/A
- IBG N/A
- EPS
- SNGX N/A
- IBG N/A
- Revenue
- SNGX $2,342.00
- IBG $2,931,243.00
- Revenue This Year
- SNGX N/A
- IBG N/A
- Revenue Next Year
- SNGX N/A
- IBG N/A
- P/E Ratio
- SNGX N/A
- IBG N/A
- Revenue Growth
- SNGX N/A
- IBG N/A
- 52 Week Low
- SNGX $1.09
- IBG $0.44
- 52 Week High
- SNGX $8.55
- IBG $3.35
- Technical
- Relative Strength Index (RSI)
- SNGX 34.55
- IBG N/A
- Support Level
- SNGX $1.09
- IBG N/A
- Resistance Level
- SNGX $1.88
- IBG N/A
- Average True Range (ATR)
- SNGX 0.14
- IBG 0.00
- MACD
- SNGX -0.01
- IBG 0.00
- Stochastic Oscillator
- SNGX 22.78
- IBG 0.00
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.